
GM
1.4K posts















My new position is $NRXS. It’s already up >30% from my initial entry less than a month ago, but I still believe this could be a multibagger from here. I intentionally kept a low profile on this one. With a sub-$100M market cap and limited liquidity, I wanted my paid subscribers to have time to research it properly before discussing it publicly. I also met with the CEO while preparing my article and clarified several key questions. If anything, that made me even more confident in the thesis. It’s been a while since I’ve been this excited about a microcap. In my view, the risk-reward is extremely compelling, especially now that several key milestones have been achieved, significantly de-risking the story. SUMMARY OF THE THESIS: - First FDA-cleared, non-invasive treatment for chronic stomach pain in children, with no competition - After almost a decade of groundwork, the key bottleneck (reimbursement) is now largely solved → commercial inflection started in January 2026 - Very strong unit economics (90%+ gross margins) with only $10-11M in revenue needed to reach profitability - $5B pediatric market with clear demand already in place just needs coverage + awareness to unlock at scale - Manufacturing is not a constraint. The company can scale from low single-digit millions to $100M+ in revenue quickly with minimal capex - Multiple near-term catalysts + long-term upside (adult market) - Sub-$100M market cap vs. potential for $50-100M revenue with only 1-2% market penetration (can easily go a lot higher over time) = asymmetric upside The thesis doesn’t rely on this at all, but in 2-3 years, this could become an M&A target at a MUCH higher valuation. Full Deep Dive (paywall removed): ⬇️ mvcinvesting.substack.com/p/my-new-posit… Not financial advice.





🚨 $NBIS announces proposed private offering of $3.75B of convertible senior notes. - $2.0B due 2031 - $1.75B due 2033 Plus an overallotment option (~$560M extra) We need the deal to close first to see the interest rate and conversion price, the most important valuation-sensitive inputs.


